The Wall Street Journal writes about the I-SPY 2 breast cancer clinical trial in both a long-form article from the perspective of a single patient, and a follow-up blog post:

A New RX for Medicine, by Ron Winslow, published October 2, 2010.
"The trial, called I-SPY 2 employs several innovative approaches to improve the notoriously slow and ineffiecient process of developing new cancer drugs. Using the latest advances in genetics, I-SPY 2 aims to match experimental drugs with the molecular makeup of tumors most likely to respond to them. And it tests multiple drugs at once, with the intent of getting the most effective ones into late-stage trials more quickly." Read the article in full on wsj.com >>

WSJ: The Health blog: I-SPY 2 Trial Tries to Shake up Cancer Drug Development, by Ron Winslow, published October 4, 2010.
"Can personalized medicine help Big Pharma get promising new cancer drugs to the market faster?" Read the blog post in full >>